JP2022511286A5 - - Google Patents
Info
- Publication number
- JP2022511286A5 JP2022511286A5 JP2021511586A JP2021511586A JP2022511286A5 JP 2022511286 A5 JP2022511286 A5 JP 2022511286A5 JP 2021511586 A JP2021511586 A JP 2021511586A JP 2021511586 A JP2021511586 A JP 2021511586A JP 2022511286 A5 JP2022511286 A5 JP 2022511286A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- binding
- pharmaceutical composition
- domain
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862724600P | 2018-08-29 | 2018-08-29 | |
| US62/724,600 | 2018-08-29 | ||
| US201862734951P | 2018-09-21 | 2018-09-21 | |
| US62/734,951 | 2018-09-21 | ||
| US201962793235P | 2019-01-16 | 2019-01-16 | |
| US62/793,235 | 2019-01-16 | ||
| US201962832830P | 2019-04-11 | 2019-04-11 | |
| US62/832,830 | 2019-04-11 | ||
| US201962890217P | 2019-08-22 | 2019-08-22 | |
| US62/890,217 | 2019-08-22 | ||
| PCT/US2019/048913 WO2020047319A1 (en) | 2018-08-29 | 2019-08-29 | Combination therapies comprising sirp alpha-based chimeric proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022511286A JP2022511286A (ja) | 2022-01-31 |
| JP2022511286A5 true JP2022511286A5 (https=) | 2022-09-06 |
Family
ID=69644684
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021511588A Pending JP2022512541A (ja) | 2018-08-29 | 2019-08-29 | Ｐｄ－１系キメラタンパク質を含む併用療法 |
| JP2021511586A Ceased JP2022511286A (ja) | 2018-08-29 | 2019-08-29 | Ｓｉｒｐアルファ系キメラタンパク質を含む併用療法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021511588A Pending JP2022512541A (ja) | 2018-08-29 | 2019-08-29 | Ｐｄ－１系キメラタンパク質を含む併用療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20210379153A1 (https=) |
| EP (2) | EP3844176A4 (https=) |
| JP (2) | JP2022512541A (https=) |
| CN (2) | CN112771067A (https=) |
| AU (2) | AU2019327494A1 (https=) |
| CA (2) | CA3109346A1 (https=) |
| IL (2) | IL281095A (https=) |
| MX (2) | MX2021002294A (https=) |
| WO (2) | WO2020047319A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022512541A (ja) * | 2018-08-29 | 2022-02-07 | シャタック ラボ，インコーポレイテッド | Ｐｄ－１系キメラタンパク質を含む併用療法 |
| US20210301019A1 (en) * | 2020-03-26 | 2021-09-30 | Aetio Biotherapy, Inc. | Bi-specific fusion proteins for depletion of regulatory t cells |
| CN116615442A (zh) * | 2020-09-08 | 2023-08-18 | 优特力克斯有限公司 | 程序性细胞死亡1多肽变体 |
| JP2023541996A (ja) * | 2020-09-17 | 2023-10-04 | シャタック ラボ，インコーポレイテッド | ＳＩＲＰ１αキメラタンパク質の臨床投与 |
| AU2021378152A1 (en) * | 2020-11-11 | 2023-06-22 | Daiichi Sankyo Company, Limited | COMBINATION OF AN ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPα ANTIBODY |
| KR102618718B1 (ko) * | 2021-01-11 | 2023-12-29 | 주식회사 유틸렉스 | 항-4-1bb 항체 및 pd-1 단백질 또는 이의 단편을 포함하는 이중특이적 에피토프 결합 단백질 및 이의 용도 |
| AU2022229900A1 (en) * | 2021-03-05 | 2023-10-05 | Shattuck Labs, Inc. | Combination therapies with sirp alpha-based chimeric proteins |
| WO2024123812A1 (en) | 2022-12-05 | 2024-06-13 | Shattuck Labs, Inc. | Fusion proteins for the treatment of cardiometabolic diseases |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| EP0745121B1 (en) | 1992-05-14 | 2007-06-20 | Baylor College Of Medicine | Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6004941A (en) | 1993-06-14 | 1999-12-21 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| DK0770397T3 (da) | 1995-10-18 | 2004-08-09 | Akzo Nobel Nv | Newcastle disease viruskombinationsvaccine |
| US6015709A (en) | 1997-08-26 | 2000-01-18 | Ariad Pharmaceuticals, Inc. | Transcriptional activators, and compositions and uses related thereto |
| US5989910A (en) | 1998-08-03 | 1999-11-23 | University Of Lausanne | Potent genetic switch allowing regulated gene expression in eukaryotic cells |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| NO2344540T3 (https=) * | 2008-10-02 | 2018-04-28 | ||
| PL3575326T3 (pl) * | 2012-12-17 | 2022-07-11 | Pf Argentum Ip Holdings Llc | Leczenie komórek chorobowych cd47+ z użyciem fuzji sirp alfa-fc |
| EP2968525A4 (en) * | 2013-03-14 | 2016-10-26 | Icahn School Med Mount Sinai | MORBUS NEWCASTLE VIRUSES AND USES THEREOF |
| IL292510A (en) * | 2013-11-05 | 2022-06-01 | Cognate Bioservices Inc | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
| SG11201705844SA (en) * | 2015-02-06 | 2017-08-30 | Heat Biologics Inc | Vector co-expressing vaccine and costimulatory molecules |
| JP6981973B2 (ja) * | 2015-10-01 | 2021-12-17 | ヒート バイオロジクス，インコーポレイテッド | Ｉ型及びｉｉ型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法 |
| AU2017378782A1 (en) * | 2016-12-20 | 2019-07-04 | Merck Sharp & Dohme Corp. | Combinations of PD-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment |
| CN110536693B (zh) * | 2017-01-05 | 2023-12-22 | 卡尔医学有限公司 | Pd1-41bbl融合蛋白及使用其的方法 |
| US20190367579A1 (en) * | 2017-02-27 | 2019-12-05 | Shattuck Labs, Inc. | Tigit- and light-based chimeric proteins |
| CN107857819A (zh) * | 2017-07-03 | 2018-03-30 | 江苏西迪尔生物技术有限公司 | 多功能融合蛋白及其应用 |
| JP2022512541A (ja) * | 2018-08-29 | 2022-02-07 | シャタック ラボ，インコーポレイテッド | Ｐｄ－１系キメラタンパク質を含む併用療法 |
-
2019
- 2019-08-29 JP JP2021511588A patent/JP2022512541A/ja active Pending
- 2019-08-29 MX MX2021002294A patent/MX2021002294A/es unknown
- 2019-08-29 EP EP19855662.3A patent/EP3844176A4/en not_active Withdrawn
- 2019-08-29 EP EP19853526.2A patent/EP3844175A4/en not_active Withdrawn
- 2019-08-29 AU AU2019327494A patent/AU2019327494A1/en not_active Abandoned
- 2019-08-29 CN CN201980063224.8A patent/CN112771067A/zh active Pending
- 2019-08-29 CA CA3109346A patent/CA3109346A1/en active Pending
- 2019-08-29 WO PCT/US2019/048913 patent/WO2020047319A1/en not_active Ceased
- 2019-08-29 US US17/266,015 patent/US20210379153A1/en not_active Abandoned
- 2019-08-29 CA CA3109354A patent/CA3109354A1/en active Pending
- 2019-08-29 WO PCT/US2019/048923 patent/WO2020047328A1/en not_active Ceased
- 2019-08-29 AU AU2019327493A patent/AU2019327493A1/en not_active Abandoned
- 2019-08-29 US US17/266,356 patent/US20210309744A1/en not_active Abandoned
- 2019-08-29 JP JP2021511586A patent/JP2022511286A/ja not_active Ceased
- 2019-08-29 MX MX2021002292A patent/MX2021002292A/es unknown
- 2019-08-29 CN CN201980067213.7A patent/CN112839952A/zh active Pending
-
2021
- 2021-02-24 IL IL281095A patent/IL281095A/en unknown
- 2021-02-25 IL IL281132A patent/IL281132A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022511286A5 (https=) | ||
| JP2022512541A5 (https=) | ||
| CN110869388B (zh) | 用于肿瘤特异性细胞消耗的Fc优化的抗CD25 | |
| JP2023509323A5 (https=) | ||
| Weiner et al. | Monoclonal antibodies: versatile platforms for cancer immunotherapy | |
| JP2024532485A (ja) | Ｃｄ１３７および腫瘍関連抗原に結合する二重特異性結合タンパク質 | |
| AU2016276706B2 (en) | Combination therapy for the treatment of cancer | |
| JP6039428B2 (ja) | 抗ｈｅｒ２抗体および組成物 | |
| JP7464525B2 (ja) | 標的療法のためのチェックポイント遮断を組み合わせる二官能性タンパク質 | |
| EP3328407A1 (en) | Combination of pd-1 antagonist with an egfr inhibitor | |
| RS62038B1 (sr) | Ciljana tgf beta inhibicija | |
| AU2013255537A1 (en) | Humanized pan-her antibody compositions | |
| CN102905723A (zh) | 抗fgfr2抗体 | |
| CN104093743A (zh) | 特异于her3的结合分子及其用途 | |
| JP7362614B2 (ja) | 癌治療のために免疫チェックポイントを調節する単一特異性および二重特異性タンパク質 | |
| CN115192718A (zh) | 抗cd47的单克隆抗体及其用途 | |
| KR20210132664A (ko) | 항pd-l1 항체 및 그의 용도 | |
| CN115197325A (zh) | 抗体在抗肿瘤治疗中的用途 | |
| JP2022512539A5 (https=) | ||
| JP2012025694A (ja) | 癌治療剤 | |
| TWI887285B (zh) | 抗ｇａｒｐ抗體與免疫調節劑之組合及其用途 | |
| JP2022503621A5 (https=) | ||
| JP2020511959A (ja) | ヒト化抗ｃｄ４０抗体 | |
| JPWO2016163433A1 (ja) | 抗ｆｇｆｒ２抗体と他剤を含む組成物 | |
| WO2026067461A1 (en) | Multispecific antibody protein and uses thereof |